CA-VIZ.AI
Viz.ai, the leader in AI-powered disease detection and care coordination, today announced it will use its VizTM RECRUIT platform to optimize patient enrollment for the NIH-funded1 Pulmonary Embolism—Thrombus Removal with Catheter-Directed Thrombolysis (PE-TRACT) clinical trial. The PE-TRACT trial will be the most rigorous randomized controlled clinical trial to date of catheter-directed therapy for pulmonary embolism, with plans to enroll 500 patients across 30-50 sites.
The PE-TRACT trial is designed to address whether catheter therapy should be routinely used to treat intermediate-risk pulmonary embolism versus anticoagulants alone. Pulmonary embolism occurs when a blood clot is trapped in an artery in the lung, blocking blood flow to part of the lung.
“The PE-TRACT trial will offer a deeper knowledge of pulmonary embolism by providing a comprehensive comparison of catheter-directed therapy plus anticoagulation to anticoagulation alone,” said Dr. Akhilesh Sista, [Principal Investigator of the PE-TRACT trial, Interventional Radiologist and Faculty, Weill Cornell Medical College]. “PE-TRACT will provide valuable insights to patients and providers regarding which approach best maintains cardiopulmonary health in the year following PE. Viz.ai’s RECRUIT tool has the potential to efficiently identify potential participants and help this important trial complete enrollment on time.”
Participating research institutions in the PE-TRACT trial will use Viz RECRUIT to find, screen, and enroll clinical trial candidates. Viz RECRUIT, an AI-powered clinical trial enrollment platform, automates the identification and triage of eligible candidates for pre-trial review, while reducing the burden on the research team. Using Viz RECRUIT, sites will be able to automatically screen patients based on pulmonary embolism and high right ventricular to left ventricular diameter (RV/LV) ratio. The cloud-based technology helps to broaden the recruitment funnel in both size and diversity and streamlines the trial enrollment workflow. To date, Viz RECRUIT has been used to screen nearly 300,000 patients and identify over 14,000 clinical trial candidates across 100 healthcare facilities.
“We’re honored to be the partner of choice for this clinical trial to accelerate vascular research using Viz RECRUIT. With our platform’s real-world accuracy and demonstrated success, researchers can use AI to identify potentially eligible trial candidates, regardless of their location, ultimately expediting the clinical trial enrollment process,” said Jayme Strauss, chief clinical officer, Viz.ai. “We aim to expand the participation and diversity of participants in clinical research to make treatments safer for all patients and advance the development of novel treatments, while empowering research teams to efficiently and consistently screen for patients and coordinate research.”
Information on the PE-TRACT trial and the Viz RECRUIT platform will be presented at the upcoming Society of Interventional Radiology Meeting on March 7 in Phoenix, Arizona. To learn more, please visit the Viz.ai website.
1 The study was funded by the National Heart, Lung, and Blood Institute, of the National Institutes of Health, under grant award number 1UG3HL155798-01A1. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
About Viz.ai, Inc.
Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase access to life-saving treatments, covering more than 200 million lives across 1,300+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz Platform is an intelligent care coordination solution that identifies more patients, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, the Viz Platform delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230304005004/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fabasoft Positioned as a Challenger in the 2026 Gartner® Magic Quadrant™ for Quality Management System Software22.1.2026 17:15:00 CET | Press release
Analyst firm publishes overview of providers of quality management software Fabasoft, a leading European cloud vendor for document and business process management, has been positioned as a Challenger with its Fabasoft Approve product by Gartner® in its first Magic Quadrant™ 2026 for Quality Management System Software. In the report, the analyst firm recognizes the company’s strengths and cautions. “Gartner defines the market for quality management system (QMS/eQMS) software as stand-alone digital solutions with embedded emerging technological capabilities that enable organizations to systematically manage, monitor and improve the quality of their products, processes and services.” In its independent report, the IT analyst firm evaluated 12 different vendors based on 15 weighted criteria. “We are delighted that Gartner has positioned our QMS as a Challenger. We see this as confirmation of our strategic direction and our technological innovations, particularly in the field of AI. At the
ClickHouse Announces Native Postgres Service, Offering a Unified Data Stack for Real-Time and AI-Driven Applications22.1.2026 17:00:00 CET | Press release
ClickHouse, Inc., the company behind the world’s fastest real-time analytical database, announced a high-performance, enterprise-grade Postgres service natively integrated with ClickHouse, delivering a unified data stack for developers building modern, real-time and AI-driven applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260122173204/en/ ClickHouse Co-Founders (left to right): Yury Izrailevsky, Aaron Katz, Alexey Milovidov The service is built in partnership with Ubicloud, Inc., an open-source cloud company delivering high-performance Postgres, led by a team with proven track record at Citus Data, Heroku, and Microsoft. This launch reinforces ClickHouse’s commitment to unifying transactional and analytical workloads on a single, scalable foundation. This announcement also builds on ClickHouse’s acquisition of PeerDB Inc. in 2024, a Postgres company whose technology is helping power real-time data synchronizati
World Governments Summit 2026 to Include Largest International Participation Yet22.1.2026 16:59:00 CET | Press release
WGS 2026 Hosts High Level Investment Forum Latin America & Caribbean, and World Laureates Summit's Global First The 2026 edition of the World Governments Summit (WGS) will host the largest ever international participation since its inception and convene several landmark forums, underlining its rising global stature and significance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260122197654/en/ The 2026 edition of the World Governments Summit is set to welcome the largest-ever international participation in the Summit's history, including 35+ heads of state and 150+ governments, as well as landmark forums, such as the World Laureates Summit, that are marking their global debut (Photo: AETOSWire) The roster of world-leading corporations and knowledge institutions at the global forum includes the International Monetary Fund (IMF), International Finance Corporation (IFC), a member of The World Bank, as well as more than 35 hea
Tageos and Wiliot Partner to Accelerate Ambient IoT, Battery-Free BLE Sensing22.1.2026 16:07:00 CET | Press release
Strategic partnership unlocks latest advancements from Tageos’ Innovation Center of Excellence, starting with the battery-free EOS-654 BLE G3 inlay for Wiliot’s Gen3 IoT Pixel sensor and the Wiliot Intelligence Platform Tageos, a global leader in RFID and wireless IoT inlays and tags, today announced a strategic partnership with ambient IoT pioneer Wiliot. The first outcome of this collaboration is the launch of a new passive Bluetooth® Low Energy (BLE) inlay, the EOS-654 BLE G3. In response growing demand for real-time location and condition monitoring across retail and logistics supply chains, this inlay was developed to support large-scale deployment of Wiliot’s Gen3 IoT Pixel sensor and the Wiliot Intelligence Platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260122940104/en/ The new EOS-654 BLE G3 features a dual-band architecture operating at 2.4 GHz and sub-1 GHz. This inlay design enables longer-range energizi
ForecastEx Appoints Renowned Forecaster Dr. Philip Tetlock to Board of Directors22.1.2026 16:00:00 CET | Press release
ForecastEx Strengthens Commitment to Predictive Excellence and Market Innovation Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, announced the appointment of Dr. Philip Tetlock to the Board of Directors of ForecastEx. Dr. Tetlock is internationally recognized for his groundbreaking expertise in forecasting, probability-based judgment, and decision-making under uncertainty, which closely aligns with ForecastEx’s prediction market model. His presence on the Board strengthens ForecastEx’s governance and regulatory oversight, adding subject-matter expertise relevant to market integrity, risk management, and outcome resolution. Thomas Peterffy, Founder and Chairman of Interactive Brokers, stated: “We are pleased to welcome Dr. Philip Tetlock to the Board of Directors of ForecastEx. Prediction markets are founded on the uncertainty of the future and the probabilities associated with potential outcomes. By aggregating consensus probabilities, forecast contracts can
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom